When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.

Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 

Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.

Meet some of the people featured in the July/August 2020 issue of The Scientist.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

A small subset of uninfected people also had SARS-CoV-2-fighting T cells, a finding that scientists are still trying to figure out.

While the finding doesn’t prove people become immune to the virus after infection, it is good news for vaccine development.

There’s a new cell-based cancer immunotherapy on the block.

The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.